These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 36984595)

  • 1. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
    Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
    Rochoń J; Kalinowski P; Szymanek-Majchrzak K; Grąt M
    World J Gastroenterol; 2024 Jun; 30(23):2964-2980. PubMed ID: 38946874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
    Jennison E; Byrne CD
    Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
    Lim S; Kim JW; Targher G
    Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.
    Alisi A; McCaughan G; Grønbæk H
    Hepatol Int; 2024 Oct; 18(Suppl 2):861-872. PubMed ID: 38995341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.
    Nováková B
    Cas Lek Cesk; 2022; 161(2):65-71. PubMed ID: 35728960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota and its metabolic potential.
    Czajkowska A; Kaźmierczak-Siedlecka K; Jamioł-Milc D; Gutowska I; Skonieczna-Żydecka K
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12971-12977. PubMed ID: 33378048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
    Drożdż K; Nabrdalik K; Hajzler W; Kwiendacz H; Gumprecht J; Lip GYH
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The microbial metabolome in metabolic-associated fatty liver disease.
    Li M; Rajani C; Zheng X; Jia W
    J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
    J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunonutritional contribution of gut microbiota to fatty liver disease.
    Fernández-Musoles R; García Tejedor A; Laparra JM
    Nutr Hosp; 2020 Feb; 37(1):193-206. PubMed ID: 31793324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
    Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
    Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
    Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.